Palvella on Track to Submit NDA for QTORIN™ in 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 03 2026
0mins
Source: Newsfilter
- NDA Submission Progress: Palvella Therapeutics is on track to submit an NDA for QTORIN™ 3.9% rapamycin anhydrous gel in the second half of 2026, aiming to provide the first FDA-approved therapy for over 30,000 individuals with microcystic lymphatic malformations in the U.S., significantly improving patient quality of life.
- Clinical Study Results: During the pre-NDA meeting with the FDA, Palvella presented efficacy and safety data from its Phase 3 SELVA study, highlighting QTORIN™'s potential as a standard treatment for microcystic lymphatic malformations, addressing a critical unmet medical need in the market.
- Regulatory Support: QTORIN™ rapamycin has received Breakthrough Therapy, Orphan Drug, and Fast Track designations from the FDA, indicating its significant potential in treating microcystic lymphatic malformations, which is expected to expedite its market entry and meet urgent patient needs.
- Future Development Strategy: Palvella plans to include supportive clinical data from the Phase 2 study and real-world evidence in its NDA submission to strengthen the application, further solidifying its market position in the rare disease treatment landscape.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PVLA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PVLA
Wall Street analysts forecast PVLA stock price to rise
15 Analyst Rating
15 Buy
0 Hold
0 Sell
Strong Buy
Current: 112.630
Low
133.00
Averages
182.20
High
212.00
Current: 112.630
Low
133.00
Averages
182.20
High
212.00
About PVLA
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Palvella on Track to Submit NDA for QTORIN™ in 2026
- NDA Submission Progress: Palvella Therapeutics is on track to submit an NDA for QTORIN™ 3.9% rapamycin anhydrous gel in the second half of 2026, aiming to provide the first FDA-approved therapy for over 30,000 individuals with microcystic lymphatic malformations in the U.S., significantly improving patient quality of life.
- Clinical Study Results: During the pre-NDA meeting with the FDA, Palvella presented efficacy and safety data from its Phase 3 SELVA study, highlighting QTORIN™'s potential as a standard treatment for microcystic lymphatic malformations, addressing a critical unmet medical need in the market.
- Regulatory Support: QTORIN™ rapamycin has received Breakthrough Therapy, Orphan Drug, and Fast Track designations from the FDA, indicating its significant potential in treating microcystic lymphatic malformations, which is expected to expedite its market entry and meet urgent patient needs.
- Future Development Strategy: Palvella plans to include supportive clinical data from the Phase 2 study and real-world evidence in its NDA submission to strengthen the application, further solidifying its market position in the rare disease treatment landscape.
See More
Palvella Therapeutics CEO to Participate in Healthcare Conference
- CEO Participation: Wes Kaupinen, Founder and CEO of Palvella Therapeutics, will participate in a fireside chat at Goldman Sachs' 47th Annual Global Healthcare Conference on June 9, 2026, which is expected to attract investor and industry attention, thereby enhancing the company's visibility in the biopharmaceutical sector.
- Live Webcast Availability: The fireside chat will be available via live webcast on Palvella's website, with an archived replay accessible for approximately 90 days post-event, ensuring that investors who cannot attend live can still access important information, thus enhancing transparency.
- Product Pipeline Overview: Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, focusing on serious rare skin diseases and vascular malformations, demonstrating the company's potential to address unmet medical needs in this niche market.
- Lead Product Candidate: Palvella's lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel, is under development for treating microcystic lymphatic malformations, indicating the company's innovative efforts in the rare disease treatment space.
See More
Palvella Secures Patent for Skin Disease Treatment
- Patent Protection Strengthened: Palvella Therapeutics has secured U.S. Patent No. 12,636,273, which covers treatments for porokeratosis, particularly disseminated superficial actinic porokeratosis (DSAP), providing robust intellectual property support for its QTORIN™ pitavastatin program, which is expected to enhance the company's market competitiveness in this area.
- Clinical Trial Plans: Palvella plans to initiate a Phase 2 clinical trial of QTORIN™ pitavastatin in the second half of 2026, aiming to provide the first treatment option for over 50,000 diagnosed DSAP patients in the U.S., addressing unmet medical needs and filling a significant market gap.
- Technological Innovation: QTORIN™ pitavastatin combines a next-generation statin with Palvella's QTORIN™ platform to enable targeted inhibition of the mevalonate pathway directly within affected skin tissue, potentially offering a novel and effective treatment option for patients with DSAP.
- Broad Market Prospects: With Palvella's ongoing R&D and patent strategy in the dermatology field, the company is poised for significant market growth in the coming years, especially given the lack of FDA-approved therapies, where the successful launch of QTORIN™ pitavastatin could yield substantial economic benefits.
See More
Palvella Named Healthcare & Life Sciences Company of the Year at 2026 PACT Awards
- Industry Recognition: Palvella Therapeutics has been awarded the Healthcare & Life Sciences Company of the Year at the 2026 Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards, highlighting its innovative efforts in treating rare skin diseases and vascular malformations, thereby enhancing its reputation in the biopharmaceutical sector.
- Team Contribution: CEO Wes Kaupinen stated that this recognition reflects the passion and commitment of the Palvella team, indicating the company's ongoing efforts to advance novel therapies aimed at providing solutions for patients lacking FDA-approved treatment options.
- Innovative Product Pipeline: Palvella is developing multiple product candidates based on its patented QTORIN™ platform, including QTORIN™ 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations and cutaneous venous malformations, showcasing its potential for clinical and commercial progress.
- Community Commitment: The PACT award selection criteria include contributions to the Greater Philadelphia life sciences ecosystem, and Palvella's recognition further solidifies its leadership position within the rapidly growing life sciences community, suggesting potential future capital formation and market impact.
See More
Palvella Releases SELVA and TOIVA Study Data
- Clinical Trial Success: In the SELVA Phase 3 study, 100% of participants aged 6-11 were rated as 'Much Improved' or 'Very Much Improved' on the mLM-IGA scale, with a mean improvement of +2.46 (p<0.001), indicating QTORIN™ rapamycin's effectiveness in pediatric patients and paving the way for potential FDA approval.
- Significant Bleeding Improvement: Among participants with moderate or worse bleeding at baseline, 87% (20/23) were rated as 'Much Improved' or 'Very Much Improved' at Week 24, with a mean improvement of +2.48 (p<0.001), demonstrating the drug's potential in managing severe symptoms.
- High Patient Satisfaction: In the SELVA study, 100% of participants reported at least some satisfaction with QTORIN™ rapamycin, with 84% indicating they were extremely satisfied or satisfied, reflecting the drug's strong acceptance and therapeutic effect among patients.
- Future Development Plans: Palvella plans to file a New Drug Application with the FDA in the second half of 2026, targeting approval in the first half of 2027, marking QTORIN™ rapamycin's potential to become the first FDA-approved treatment for microcystic lymphatic malformations.
See More
Palvella Releases New Data on QTORIN™ Efficacy
- Clinical Trial Results: In the TOIVA trial, 100% of patients with bleeding at baseline showed a statistically significant average improvement of 2.5 points in cVM-IGA bleeding scores at Week 12 (p=0.003), indicating that QTORIN™ rapamycin significantly reduces bleeding and enhances patient quality of life, potentially becoming the first FDA-approved treatment.
- Patient Satisfaction: All patients with bleeding at baseline reported being 'satisfied' or 'very satisfied' on the Treatment Satisfaction Questionnaire, highlighting QTORIN™ rapamycin's importance in improving overall treatment experience, which may enhance market acceptance.
- Quality of Life Burden: Baseline patient interviews revealed the multidimensional impact of cutaneous venous malformations on patients' lives, including pain, functional limitations, and mental health issues, emphasizing the significance of patient-reported outcomes in clinical development and guiding future treatment directions.
- Market Potential: With over 75,000 individuals in the U.S. suffering from cutaneous venous malformations and lacking effective treatments, the successful development of QTORIN™ rapamycin could not only fill a significant market gap but also provide Palvella with substantial commercial opportunities and competitive advantages.
See More
Palvella on Track to Submit NDA for QTORIN™ in 2026
- NDA Submission Progress: Palvella Therapeutics is on track to submit an NDA for QTORIN™ 3.9% rapamycin anhydrous gel in the second half of 2026, aiming to provide the first FDA-approved therapy for over 30,000 individuals with microcystic lymphatic malformations in the U.S., significantly improving patient quality of life.
- Clinical Study Results: During the pre-NDA meeting with the FDA, Palvella presented efficacy and safety data from its Phase 3 SELVA study, highlighting QTORIN™'s potential as a standard treatment for microcystic lymphatic malformations, addressing a critical unmet medical need in the market.
- Regulatory Support: QTORIN™ rapamycin has received Breakthrough Therapy, Orphan Drug, and Fast Track designations from the FDA, indicating its significant potential in treating microcystic lymphatic malformations, which is expected to expedite its market entry and meet urgent patient needs.
- Future Development Strategy: Palvella plans to include supportive clinical data from the Phase 2 study and real-world evidence in its NDA submission to strengthen the application, further solidifying its market position in the rare disease treatment landscape.
See More
Palvella Therapeutics CEO to Participate in Healthcare Conference
- CEO Participation: Wes Kaupinen, Founder and CEO of Palvella Therapeutics, will participate in a fireside chat at Goldman Sachs' 47th Annual Global Healthcare Conference on June 9, 2026, which is expected to attract investor and industry attention, thereby enhancing the company's visibility in the biopharmaceutical sector.
- Live Webcast Availability: The fireside chat will be available via live webcast on Palvella's website, with an archived replay accessible for approximately 90 days post-event, ensuring that investors who cannot attend live can still access important information, thus enhancing transparency.
- Product Pipeline Overview: Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, focusing on serious rare skin diseases and vascular malformations, demonstrating the company's potential to address unmet medical needs in this niche market.
- Lead Product Candidate: Palvella's lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel, is under development for treating microcystic lymphatic malformations, indicating the company's innovative efforts in the rare disease treatment space.
See More
Palvella Secures Patent for Skin Disease Treatment
- Patent Protection Strengthened: Palvella Therapeutics has secured U.S. Patent No. 12,636,273, which covers treatments for porokeratosis, particularly disseminated superficial actinic porokeratosis (DSAP), providing robust intellectual property support for its QTORIN™ pitavastatin program, which is expected to enhance the company's market competitiveness in this area.
- Clinical Trial Plans: Palvella plans to initiate a Phase 2 clinical trial of QTORIN™ pitavastatin in the second half of 2026, aiming to provide the first treatment option for over 50,000 diagnosed DSAP patients in the U.S., addressing unmet medical needs and filling a significant market gap.
- Technological Innovation: QTORIN™ pitavastatin combines a next-generation statin with Palvella's QTORIN™ platform to enable targeted inhibition of the mevalonate pathway directly within affected skin tissue, potentially offering a novel and effective treatment option for patients with DSAP.
- Broad Market Prospects: With Palvella's ongoing R&D and patent strategy in the dermatology field, the company is poised for significant market growth in the coming years, especially given the lack of FDA-approved therapies, where the successful launch of QTORIN™ pitavastatin could yield substantial economic benefits.
See More
Palvella Named Healthcare & Life Sciences Company of the Year at 2026 PACT Awards
- Industry Recognition: Palvella Therapeutics has been awarded the Healthcare & Life Sciences Company of the Year at the 2026 Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards, highlighting its innovative efforts in treating rare skin diseases and vascular malformations, thereby enhancing its reputation in the biopharmaceutical sector.
- Team Contribution: CEO Wes Kaupinen stated that this recognition reflects the passion and commitment of the Palvella team, indicating the company's ongoing efforts to advance novel therapies aimed at providing solutions for patients lacking FDA-approved treatment options.
- Innovative Product Pipeline: Palvella is developing multiple product candidates based on its patented QTORIN™ platform, including QTORIN™ 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations and cutaneous venous malformations, showcasing its potential for clinical and commercial progress.
- Community Commitment: The PACT award selection criteria include contributions to the Greater Philadelphia life sciences ecosystem, and Palvella's recognition further solidifies its leadership position within the rapidly growing life sciences community, suggesting potential future capital formation and market impact.
See More
Palvella Releases SELVA and TOIVA Study Data
- Clinical Trial Success: In the SELVA Phase 3 study, 100% of participants aged 6-11 were rated as 'Much Improved' or 'Very Much Improved' on the mLM-IGA scale, with a mean improvement of +2.46 (p<0.001), indicating QTORIN™ rapamycin's effectiveness in pediatric patients and paving the way for potential FDA approval.
- Significant Bleeding Improvement: Among participants with moderate or worse bleeding at baseline, 87% (20/23) were rated as 'Much Improved' or 'Very Much Improved' at Week 24, with a mean improvement of +2.48 (p<0.001), demonstrating the drug's potential in managing severe symptoms.
- High Patient Satisfaction: In the SELVA study, 100% of participants reported at least some satisfaction with QTORIN™ rapamycin, with 84% indicating they were extremely satisfied or satisfied, reflecting the drug's strong acceptance and therapeutic effect among patients.
- Future Development Plans: Palvella plans to file a New Drug Application with the FDA in the second half of 2026, targeting approval in the first half of 2027, marking QTORIN™ rapamycin's potential to become the first FDA-approved treatment for microcystic lymphatic malformations.
See More
Palvella Releases New Data on QTORIN™ Efficacy
- Clinical Trial Results: In the TOIVA trial, 100% of patients with bleeding at baseline showed a statistically significant average improvement of 2.5 points in cVM-IGA bleeding scores at Week 12 (p=0.003), indicating that QTORIN™ rapamycin significantly reduces bleeding and enhances patient quality of life, potentially becoming the first FDA-approved treatment.
- Patient Satisfaction: All patients with bleeding at baseline reported being 'satisfied' or 'very satisfied' on the Treatment Satisfaction Questionnaire, highlighting QTORIN™ rapamycin's importance in improving overall treatment experience, which may enhance market acceptance.
- Quality of Life Burden: Baseline patient interviews revealed the multidimensional impact of cutaneous venous malformations on patients' lives, including pain, functional limitations, and mental health issues, emphasizing the significance of patient-reported outcomes in clinical development and guiding future treatment directions.
- Market Potential: With over 75,000 individuals in the U.S. suffering from cutaneous venous malformations and lacking effective treatments, the successful development of QTORIN™ rapamycin could not only fill a significant market gap but also provide Palvella with substantial commercial opportunities and competitive advantages.
See More
